Boston Scientific delivered a strong finish to 2025, reporting Q4 revenue of $5.286 billion (+15.9% reported, +12.7% organic) and full-year revenue of $20.74 billion (+19.9% reported, +15.8% organic). Adjusted EPS grew 22% for the full year to $3.06, driven by a 100-basis point expansion in adjusted operating margins to 28.0%. Growth was broad-based, led by Electrophysiology (EP) up 35% organically in Q4 and WATCHMAN up 29%, while Urology faced supply chain headwinds. For 2026, the company guides for organic revenue growth of 10% to 11% and EPS growth of 12% to 14%, despite temporary headwinds from the AXIOS device removal and ACURATE discontinuation in the first half.
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Revenue | $5.286 billion | +15.9% reported / +12.7% organic |
| Full Year 2025 Revenue | $20.74 billion | +19.9% reported / +15.8% organic |
| Q4 2025 Adjusted EPS | $0.80 | +15% year-over-year |
| Full Year 2025 Adjusted EPS | $3.06 | +22% year-over-year |
| Full Year 2025 Adjusted Operating Margin | 28.0% | +100 basis points year-over-year |
| Q4 EP Organic Growth | 35% | Strong double-digit growth |
| 2026 Organic Revenue Guidance | 10% to 11% | N/A |
| 2026 EPS Guidance | $3.43 to $3.49 | +12% to +14% |
Electrophysiology (EP) Market Leadership: Management emphasized that BSX is maintaining a dominant position in PFA with approximately 65% market share, despite competitive entries. They are guiding for the EP market to grow 15% in 2026, a figure notably lower than sell-side estimates, effectively resetting expectations. The strategy relies on an 'ecosystem approach' including mapping (OPAL), focal therapy (FARAPOINT), and concomitant procedures to defend share.
WATCHMAN Clinical Catalysts: The upcoming CHAMPION trial data presentation (March 28) is a major strategic focus. Management believes a positive result could support WATCHMAN as a first-line therapy, expanding the addressable patient population from 5 million to 20 million globally. This, combined with the SIMPLIFY trial for drug regimens, aims to drive sustained double-digit growth in the franchise.
M&A-Driven Portfolio Expansion: The announced acquisition of Penumbra (expected close 2026) signals a strategic move into high-growth adjacencies like neurovascular and mechanical thrombectomy. Management highlighted the deal as both strategically and financially attractive, noting it will enhance the Weighted Average Market Growth Rate (WAMGR) and strengthen the cardiovascular portfolio.
Margin Expansion & Capital Deployment: BSX delivered 100 bps of operating margin expansion in 2025 and is guiding for another 50-75 bps in 2026. This leverage is funding reinvestment into R&D and the supply chain. The company maintains an active M&A pipeline (Nalu closed, Valencia and Penumbra pending) while targeting 70-80% free cash flow conversion.
International Growth Diversification: Management highlighted strong performance in Japan and China (mid-teens growth), driven by EP and WATCHMAN. Recent regulatory approvals in China (FARAWAVE NAV) and persistent AF indications provide new vectors for growth, reducing reliance on US market dynamics.
Urology Segment Underperformance: The Urology business missed expectations in 2025 due to supply chain issues and commercial integration challenges with the Axonics acquisition. Management admitted performance was 'below our expectations,' though they forecast a return to market growth in 2026. This raises questions about the integration capability for larger deals like Penumbra.
Endoscopy Product Recall: A product removal for certain sizes of the AXIOS device due to a 'manufacturing variation' will impact Endoscopy growth in the first half of 2026. Management expects the device back by mid-year, but the disruption creates a near-term growth headwind and raises quality control concerns.
ACURATE Discontinuation Drag: The discontinuation of the ACURATE heart valve is a 150 basis point headwind on Q1 2026 growth. This represents a significant loss of revenue that the company must offset with new product launches, highlighting the risk of portfolio gaps.
EP Market Size Skepticism: There is a clear divergence between management's view of the EP market (18-20% growth in Q4) and the Street's view (~25%). If the market is actually slowing faster than management admits, or if competitors are taking share more aggressively, BSX's premium valuation multiple could be at risk.
CRM Business Stagnation: Cardiac Rhythm Management (CRM) grew only 1% organically in Q4 and full year 2025. While management expects growth closer to market in 2026, this segment remains a laggard compared to the high-growth EP and WATCHMAN units.
Overall: Management displayed a high level of confidence regarding the company's execution and long-term strategy, while becoming notably defensive and firm when addressing analyst skepticism about the size and growth rate of the EP market. They were transparent about specific operational headwinds like the AXIOS device issue but emphasized the strength of their diversified portfolio.
Confidence: HIGH - Management consistently exceeded guidance in 2025 and reaffirmed long-term targets (10%+ growth through 2028). They pushed back assertively against bearish narratives regarding EP market saturation, insisting on their internal market data over Street estimates.
Management guided for organic revenue growth of 10% to 11% for the full year 2026. This includes a 50 basis point tailwind from foreign exchange. For Q1 specifically, organic growth is expected to be 8.5% to 10%, impacted by the ACURATE discontinuation and AXIOS device removal.
The company expects full year 2026 adjusted EPS in the range of $3.43 to $3.49, representing 12% to 14% growth versus 2025. Q1 EPS is expected to be $0.78 to $0.80.
Boston Scientific expects to expand adjusted operating margins by 50 to 75 basis points in 2026, progressing toward their long-term goal of 150 basis points of expansion.
Free cash flow is expected to be approximately $4.2 billion in 2026, with a long-term target of 70% to 80% conversion.
Hedging & Uncertainty: Management utilized specific quantitative guidance but employed hedging language regarding market definitions and competitive dynamics. For example, they qualified the EP market size as 'kind of an 18% to 20% range' rather than a definitive figure, and used 'approximately' and 'roughly in line' when discussing 2026 margins. They also used temporal hedges like 'as we look ahead' and 'over the long-range plan' to frame expectations, suggesting a desire to manage short-term investor expectations while maintaining long-term credibility.
We think the market was kind of an 18% to 20% range... We don't think it grew 25% in the fourth quarter. - Michael Mahoney
If we were doing our Investor Day today, we'd get the same numbers. - Michael Mahoney
Our performance in euro this year was below our expectations... - Michael Mahoney
We anticipate lower Endo growth in the first half of the year as a result. - Michael Mahoney
We expect our differentiated financial performance to continue... - Michael Mahoney
Analyst Sentiment: Analysts were skeptical and probing, particularly regarding the Electrophysiology (EP) market size and US growth trajectory. Multiple analysts (JPMorgan, Wells Fargo, Bank of America) pressed for clarification on why US EP growth appeared flat sequentially and if market share was being lost to competitors. There was also significant interest in the WATCHMAN CHAMPION trial and the impact of recent clinical data.
Management Responses: Management was direct and firm in their responses, particularly CEO Mike Mahoney. They pushed back against the narrative of a 25% EP market growth, insisting their data suggests 18-20%. They were transparent about headwinds (AXIOS, ACURATE) and confident in the long-term outlook, refusing to yield on the sustainability of their growth profile despite the tough Q1 comparison.
EP Market Size & Share: Analysts questioned the deceleration of US EP growth and the validity of market size estimates. Management defended their position, citing 35% global growth and 65% PFA share, arguing the market is growing 15-20%, not 25%.
WATCHMAN Clinical Trials: Questions focused on the impact of recent competitor trials and the upcoming CHAMPION data. Management confirmed no negative impact from competitor trials and expressed high optimism for CHAMPION to expand indications.
2026 Guidance & H1 Headwinds: Analysts sought to understand the softer Q1 guide (8.5-10%). Management explained the impact of the AXIOS recall and ACURATE discontinuation, which will annualize in H2, setting up a stronger second half.
M&A Strategy: Questions centered on the Penumbra acquisition and sales force deployment. Management emphasized the strategic fit and the addition of high-growth neurovascular and thrombectomy portfolios.
Boston Scientific delivered an exceptional 2025, with 15.8% organic growth and significant margin expansion, proving the strength of its diversified portfolio. The company is successfully leveraging its leadership in high-growth markets like PFA and WATCHMAN, while the pending Penumbra acquisition adds another high-growth vector. Although management is guiding for a more normalized 10-11% growth in 2026 and faces near-term headwinds from the AXIOS recall and ACURATE discontinuation, the long-term algorithm remains intact. The reiteration of 2028 goals (10%+ sales growth, 150 bps margin expansion) signals confidence. The primary risk is a potential slowdown in the EP market or loss of share that exceeds management's conservative estimates, but the current valuation and execution justify a positive stance. Key factors to monitor include the CHAMPION trial results in March and the share trend in US PFA throughout 2026.
The Pulsed Field Ablation (PFA) market is maturing rapidly, with US penetration reaching approximately 70%. Management commentary suggests a divergence in market perception, where they estimate growth at 18-20% versus the Street's 25%, indicating a potential normalization from hyper-growth to a more sustainable 'high growth' phase. This reflects a broader trend in MedTech where new technologies see explosive initial adoption that eventually stabilizes as penetration saturates.